培美曲塞联合卡铂化疗后培美曲塞维持治疗晚期肺腺癌的临床研究

摘要

Objective To investigate the clinical efficacy of pemetrexed maintenance following combination of peme-trexed/carboplatin chemotherapy in the treatment of advanced lung adenocarcinoma,and its impact on quality of life. Methods 49 patients with stage ⅢB ~ Ⅳ lung adenocarcinoma was treated with pemetrexed combined with carboplatin as first line treat-ment,and followed maintenance chemotherapy using pemetrexed d at every cycle. Results Patients received at least 2 cycles of maintenance chemotherapy.The result showed 1 case of remission (2. 0%) (CR),partial remission (PR) in 19 cases (38. 8%),stable (SD) in 24 cases(49. 0%),progression (PD) in 5 cases(10. 2%),disease control rate (DCR) 89. 8%,dis-ease remission rate (ORR) 40. 8%,the PFS was 7. 5 months. Conclusion Pemetrexed with carboplatin in advanced lung adeno-carcinoma patients after chemotherapy with pemetrexed maintenance therapy can maintain disease progression,prolong PFS,im-prove quality of life,and reduce toxicity and side effects.%目的 探讨培美曲塞联合卡铂化疗后应用培美曲塞维持治疗晚期肺腺癌的临床疗效和对患者生活质量的影响.方法 对49例ⅢB~Ⅳ期肺腺癌患者,一线采用培美曲塞联合卡铂化疗后,应用培美曲塞单药维持化疗.结果患者至少接受2个周期维持治疗,缓解(CR)1例(2.0%),部分缓解(PR)19例(38.8%),稳定(SD)24例(49.0%),进展(PD)5例(10.2%),疾病控制率(DCR)89.8%,疾病缓解率(ORR)40.8%,PFS为7.5个月.结论 晚期肺腺癌患者培美曲塞联合卡铂化疗后培美曲塞同药维持治疗能够控制病情进展,延长 PFS,改善患者生活质量,且毒副作用小,耐受性良好.